IE883430L - Novel fluorocytidine derivatives - Google Patents

Novel fluorocytidine derivatives

Info

Publication number
IE883430L
IE883430L IE883430A IE343088A IE883430L IE 883430 L IE883430 L IE 883430L IE 883430 A IE883430 A IE 883430A IE 343088 A IE343088 A IE 343088A IE 883430 L IE883430 L IE 883430L
Authority
IE
Ireland
Prior art keywords
novel
hydrogen
radical
fluorocytidine derivatives
compounds
Prior art date
Application number
IE883430A
Original Assignee
Sean Anthony Donegan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sean Anthony Donegan filed Critical Sean Anthony Donegan
Publication of IE883430L publication Critical patent/IE883430L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The novel 5'-deoxy-5-fluorocytidine derivatives of formula <IMAGE> (I) wherein R1, R2 and R3 are hydrogen or an easily hydrolyzable radical under physiological conditions, with the proviso that, at least one or R1, R2 and R3 is an easily hydrolyzable radical under physiological conditions, as well as hydrates of solvates of these compounds have antitumor properties. They can be prepared from compounds of formula I, wherein R1 is hydrogen or an amino-protecting radical and R2 and R3 are hydrogen or a hydroxy-protecting radical or taken together are a cyclic hydroxy-protecting radical. [US4966891A]
IE883430A 1987-11-17 1988-11-16 Novel fluorocytidine derivatives IE883430L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17

Publications (1)

Publication Number Publication Date
IE883430L true IE883430L (en) 1989-05-17

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
IE883430A IE883430L (en) 1987-11-17 1988-11-16 Novel fluorocytidine derivatives

Country Status (35)

Country Link
US (1) US4966891A (en)
EP (1) EP0316704B1 (en)
JP (1) JPH0678350B2 (en)
KR (1) KR970000241B1 (en)
CN (1) CN1022688C (en)
AR (1) AR247217A1 (en)
AT (1) ATE124951T1 (en)
AU (1) AU619220B2 (en)
CA (1) CA1327358C (en)
CS (1) CS274486B2 (en)
DE (2) DE3854148D1 (en)
DK (1) DK170893B1 (en)
DZ (1) DZ1270A1 (en)
ES (1) ES2074429T3 (en)
FI (1) FI89804C (en)
GR (1) GR3017686T3 (en)
HK (1) HK1003114A1 (en)
HU (1) HU199866B (en)
IE (1) IE883430L (en)
IL (1) IL88363A0 (en)
IS (1) IS1895B (en)
LT (1) LT2185B (en)
LU (1) LU90769I2 (en)
LV (1) LV5624A3 (en)
MC (1) MC1992A1 (en)
MX (1) MX173347B (en)
NL (1) NL300045I2 (en)
NO (2) NO171167C (en)
NZ (1) NZ226923A (en)
PH (1) PH25641A (en)
PT (1) PT89009B (en)
SU (1) SU1736342A3 (en)
UA (1) UA19333A (en)
YU (1) YU47122B (en)
ZA (1) ZA888428B (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (en) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (en) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CA2550299C (en) * 2003-12-22 2010-03-30 Christopher R. Roberts Process for fluorocytidine derivatives
EP1718625A1 (en) * 2004-02-18 2006-11-08 AstraZeneca AB Compounds
ATE426597T1 (en) * 2004-02-18 2009-04-15 Astrazeneca Ab BENZAMIDE DERIVATIVES AND THE USE THEREOF AS GLUCOCINASE ACTIVATE AGENTS
CN100383128C (en) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 Ramification of N-carbethoxy cytosine and preparation method and application
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (en) 2004-09-08 2011-09-02 삼성전자주식회사 Thin film transistor array panel and manufacturing method thereof
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
BRPI0516595A (en) 2004-10-16 2008-09-23 Astrazeneca Ab process for making a compound, and, compound
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
CN113952338A (en) 2005-02-03 2022-01-21 综合医院公司 Methods of treating gefitinib resistant cancers
NO322682B1 (en) * 2005-03-18 2006-11-27 Clavis Pharma Asa Use of gemcitabine derivatives for the preparation of oral dosage forms in cancer treatment, as well as such oral dosage forms
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500442A (en) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ 2-Heterocyclyloxybenzoylaminoheterocyclyl compounds as modulators of glucokinase for treating type 2 diabetes
EP2305674A1 (en) 2005-07-09 2011-04-06 AstraZeneca AB Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CN100569790C (en) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 Synthetic N 4The method of-acyl group-5 ＇-deoxidation-5-fluorcytidines
JP2009501734A (en) * 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド How to treat cancer
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
BRPI0618042A2 (en) 2005-11-04 2011-08-16 Wyeth Corp uses of a rapamycin and herceptin, product, pharmaceutical package, and, pharmaceutical composition
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CN100425617C (en) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 Fluoropyrimidine compound carbalkoxylation method
UY30822A1 (en) 2006-12-21 2008-07-31 Astrazeneca Ab NEW CRYSTAL FORM OF 3 - {[5-AZETIDIN-1-YLCABONYL) PYRAZIN-2-YL] OXY} -5- [1-METHYLETHYLOXY] -N-1H-PYRAZOL-3-YLBENZAMIDA, COMPOSITIONS CONTAINING AND PREPARATION, PROCESSING AND PREPARATION APPLICATIONS
ITMI20070435A1 (en) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2 ', 3'-DI-O-acyl-5-FLUORONUCLEOSIDI
MX2009011255A (en) * 2007-04-20 2009-11-23 Reddys Lab Ltd Dr Process for preparing capecitabine.
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20090122955A (en) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. Process for the preparation of capecitabine
SI2310011T1 (en) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
BRPI0916694B1 (en) * 2008-08-04 2021-06-08 Wyeth Llc use of neratinib in combination with capecitabine to treat erbb-2 positive metastatic breast cancer, kit and product comprising the same
BRPI0917589A2 (en) 2008-08-04 2015-11-17 Astrazeneca Ab compound, pharmaceutical composition, use of a compound, method for treating disease, process, pharmaceutical combination, and reaction of methyloxyran-2-carboxylate (ix) with a roh alcohol
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (en) * 2009-01-23 2013-07-31 高峰 Cytarabine derivatives and purposes thereof in resisting cancers and tumors
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
EP4218760A3 (en) 2009-04-06 2023-08-16 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (en) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 Nucleoside compound, preparation method and application thereof
KR20120037932A (en) * 2009-07-23 2012-04-20 시노팜 타이완 리미티드 Process for producing flurocytidine derivatives
ES2584433T3 (en) 2010-03-12 2016-09-27 Genzyme Corporation Combination therapy to treat breast cancer
JP2015518705A (en) 2012-04-02 2015-07-06 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of biologics and proteins associated with human diseases
JP2015516143A (en) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified polynucleotides for the production of proteins associated with human disease
US9328106B2 (en) * 2012-09-26 2016-05-03 Genentech, Inc. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
JP2015536954A (en) * 2012-11-07 2015-12-24 ズカイ スオ Substituted gemcitabine arylamide analogues
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2968382B1 (en) * 2013-03-15 2018-03-07 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (en) * 2013-09-09 2015-09-09 南通大学 Farnesyl thiosalicylic acid-nucleosides conjugate, its preparation method and medicinal use thereof
AU2014329452B2 (en) 2013-10-03 2019-06-20 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
AU2017286852B2 (en) * 2016-06-28 2021-05-06 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN112004537A (en) 2018-01-09 2020-11-27 穿梭药业公司 Selective histone deacetylase inhibitors for the treatment of human diseases
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339A (en) * 2018-01-19 2020-10-20 纽科利制药公司 5-fluorouracil compounds
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
CN109651467A (en) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 A kind of capecitabine impurity and preparation method thereof
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
WO2022020811A1 (en) 2020-07-24 2022-01-27 Strand Therapeutics, Inc. Lipidnanoparticle comprising modified nucleotides
JP2024503000A (en) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド Expression constructs and their use
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (en) * 1982-06-14 1985-06-14 Synthelabo PURIC AND PYRIMID BASED XYLOSIDE AND LYXOSIDE PHARMACEUTICAL COMPOSITIONS
JPS61112093A (en) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk Nucleotide derivative

Also Published As

Publication number Publication date
KR890008162A (en) 1989-07-10
LT2185B (en) 1993-10-15
JPH01153696A (en) 1989-06-15
JPH0678350B2 (en) 1994-10-05
DZ1270A1 (en) 2004-09-13
US4966891A (en) 1990-10-30
NO885106L (en) 1989-05-18
CN1033183A (en) 1989-05-31
PH25641A (en) 1991-08-21
FI885329A0 (en) 1988-11-17
DK170893B1 (en) 1996-03-04
GR3017686T3 (en) 1996-01-31
LU90769I2 (en) 2001-07-02
EP0316704A2 (en) 1989-05-24
NO171167C (en) 1993-02-03
PT89009B (en) 1993-02-26
EP0316704B1 (en) 1995-07-12
CA1327358C (en) 1994-03-01
DK640388A (en) 1989-05-18
NZ226923A (en) 1990-10-26
NO885106D0 (en) 1988-11-16
ES2074429T3 (en) 1995-09-16
FI89804C (en) 1993-11-25
ZA888428B (en) 1989-06-28
DE3854148D1 (en) 1995-08-17
YU209188A (en) 1990-08-31
NL300045I2 (en) 2002-01-02
HK1003114A1 (en) 1998-10-09
AR247217A1 (en) 1994-11-30
HUT48267A (en) 1989-05-29
NO2001013I2 (en) 2006-05-01
FI885329A (en) 1989-05-18
ATE124951T1 (en) 1995-07-15
CS274486B2 (en) 1991-04-11
MX13836A (en) 1993-10-01
IL88363A0 (en) 1989-06-30
FI89804B (en) 1993-08-13
UA19333A (en) 1997-12-25
YU47122B (en) 1994-12-28
IS1895B (en) 2003-10-20
SU1736342A3 (en) 1992-05-23
IS3412A7 (en) 1989-05-18
NL300045I1 (en) 2001-08-01
LV5624A3 (en) 1994-05-10
MC1992A1 (en) 1989-11-30
EP0316704A3 (en) 1990-11-22
DK640388D0 (en) 1988-11-16
DE10199027I2 (en) 2002-01-31
HU199866B (en) 1990-03-28
AU2516888A (en) 1989-05-25
PT89009A (en) 1988-12-01
KR970000241B1 (en) 1997-01-08
CS747588A2 (en) 1990-09-12
DE10199027I1 (en) 2001-08-02
NO171167B (en) 1992-10-26
CN1022688C (en) 1993-11-10
MX173347B (en) 1994-01-03
AU619220B2 (en) 1992-01-23

Similar Documents

Publication Publication Date Title
IE883430L (en) Novel fluorocytidine derivatives
AU4628293A (en) Intermediates for use in the preparation of (benzylidene)- azolylmethylcycloalkane or-alkenes
GR3007919T3 (en)
TW372239B (en) N-oxycarbonyl substituted 5&#39;-deoxy-5-fluorcytidines
EP0682033A3 (en) Hydrolysable and polymerisable silanes
CA2112331A1 (en) Novel naphthalene derivatives
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
EP0394496A4 (en) Glycoside derivatives, polymers containing glycoside derivatives, process for their preparation, and use of said polymers
AU1739092A (en) 1-methylcarbapenem derivatives, their preparation and their use as antibiotics
AU583543B2 (en) New adamantanamine derivatives, processes for their preparation and drugs in which they are present
EP0765939A3 (en)
IL100266A0 (en) Fluorine compounds
ES468125A1 (en) Insecticidal (2,3-dihydro-2,2-dimethylbenzofuran-7-yloxy-N-methylcarbamoyl)-(N&#39;-alkoxycarbamoyl)-sulphides
AU600054B2 (en) 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m- phenylene pgi2 derivatives
MY103552A (en) Saccharide derivatives
EP0401684A3 (en) Method for the preparation of organosiloxanes
CA2039874A1 (en) 4&#39;-demethylepipodophyllotoxin glycosides
CA2042745A1 (en) Novel hardenable compositions
AU5559286A (en) Difluorocyclopropane derivatives
DE69000019D1 (en) 4&#39;-epi-4&#39;-aminoanthracycline.
AU7649391A (en) 3&#39;-deamino-4&#39;-deoxy-4&#39;-amino-8-fluoroanthracyclines and processes for their preparation
AU547237B2 (en) Poly(disulphides) having immune response activity
AU8251087A (en) Non-aqueous polymeric dispersion compositions and methods for preparing them
ES2012564A6 (en) 4-demethoxy-4&#39;-amino-4&#39;-deoxy-anthracycline derivatives

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Free format text: PRODUCT NAME: CAPECITABINE OR A HYDRATE OR SOLVATE THEREOF

Spc suppl protection certif: SPC008/2001

Filing date: 20040510

Expiry date: 20131115

MK9A Patent expired